ATM and cancer: In a prospective cohort study of 419 patients with metastatic castration-resistant prostate cancer (68 harboring germline pathogenic variants in genes involved in DNA damage repair mechanisms, including 14 with BRCA2, 8 with ATM, and 4 with BRCA1), cancer-specific survival rates were significantly lower in individuals with a germline BRCA2 pathogenic variant than in individuals without germline pathogenic variants in genes involved in DNA damage repair mechanisms [23].